An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90022
- Academic Medical Research Institute (AMRI)
-
Northridge, California, United States, 91324
- Amicis Research Center
-
Victorville, California, United States, 92395
- Kidney and Hypertension Center - Apple Valley
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Center
-
Denver, Colorado, United States, 80230
- Colorado Kidney Care (Denver Nephrology)
-
-
Idaho
-
Nampa, Idaho, United States, 83687
- Boise Kidney and Hypertension Institute
-
-
Illinois
-
Hinsdale, Illinois, United States, 60521
- NANI Research, LLC
-
-
Michigan
-
Roseville, Michigan, United States, 48066
- St. Clair Nephrology
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Clinical Research Consultants
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404-2743
- Southeast Renal Research Institute
-
-
Texas
-
Houston, Texas, United States, 77054
- Prolato Clinical Research Center
-
San Antonio, Texas, United States, 78212
- Clinical Advancement Center, PLLC
-
Webster, Texas, United States, 77598
- Tranquility Research
-
-
Utah
-
Salt Lake City, Utah, United States, 84115
- Utah Kidney Center
-
-
Washington
-
Spokane, Washington, United States, 99204
- Providence Medical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants with FSGS/TR-MCD who have completed the treatment phase from an interventional clinical study with GFB-887. Participants who were discontinued for rising proteinuria from a GFB-887 interventional study may be considered for enrollment following consultation with the Medical Monitor.
- Participants who enrolled in any other interventional study during the time between completion of the prior GFB-887 interventional study and this study may be considered for enrollment following consultation with the Medical Monitor.
Exclusion Criteria:
- Participant is unable to take oral medications
- Participant has an unstable medical condition based on medical history, physical examination, laboratory tests, ECGs, vital signs or is otherwise unstable in the judgement of the Investigator which would pose a risk to the participant or interfere with study evaluation, procedures, or completion
- Evidence of significant hypersensitivity, intolerance, or allergy to any component of investigational product GFB-887
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 200 mg Dose Cohort
Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level.
|
GFB-887 is a potent, small molecule inhibitor of TRPC5.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence and severity of adverse events
Time Frame: Approximately 3 years
|
Incidence and severity of adverse events
|
Approximately 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent reduction in urine protein:creatinine ratio (UPCR) from baseline
Time Frame: Approximately 3 years
|
Percent reduction in urine protein:creatinine ratio (UPCR) from baseline
|
Approximately 3 years
|
|
Proportion of participants achieving modified partial remission status
Time Frame: Approximately 3 years
|
Proportion of participants achieving modified partial remission status
|
Approximately 3 years
|
|
Proportion of participants achieving complete remission status
Time Frame: Approximately 3 years
|
Proportion of participants achieving complete remission status
|
Approximately 3 years
|
|
Proportion of participants with a UPCR decrease of at least 30% from baseline
Time Frame: Approximately 3 years
|
Proportion of participants with a UPCR decrease of at least 30% from baseline
|
Approximately 3 years
|
|
Proportion of participants with a UPCR decrease of at least 40% from baseline
Time Frame: Approximately 3 years
|
Proportion of participants with a UPCR decrease of at least 40% from baseline
|
Approximately 3 years
|
|
Proportion of participants with a UPCR decrease of at least 50% from baseline
Time Frame: Approximately 3 years
|
Proportion of participants with a UPCR decrease of at least 50% from baseline
|
Approximately 3 years
|
|
Time to maximal percent reduction in UPCR from baseline
Time Frame: Approximately 3 years
|
Time to maximal percent reduction in UPCR from baseline
|
Approximately 3 years
|
|
Summary of plasma pharmacokinetic (PK) concentrations: Dose proportionality
Time Frame: Approximately 3 years
|
Dose proportionality of GFB-887
|
Approximately 3 years
|
|
Summary of Plasma PK concentrations (AUCinf)
Time Frame: Approximately 3 years
|
Area under the plasma concentration-time curve from time zero to infinity
|
Approximately 3 years
|
|
Summary of Plasma PK concentrations (AUClast)
Time Frame: Approximately 3 years
|
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration
|
Approximately 3 years
|
|
Summary of Plasma PK concentrations (Cmax)
Time Frame: Approximately 3 years
|
Maximum observed plasma concentration
|
Approximately 3 years
|
|
Changes in estimated glomerular filtration rate (eGFR) including slope
Time Frame: Approximately 3 years
|
Glomerular filtration rate will be estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on serum creatinine
|
Approximately 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GFB-887-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.